SPECTRUM PHARMA Forum: Community User: AdlerX8

...

The company also announced today that the FDA has accepted for review the BLA for ROLONTIS for the treatment of chemotherapy-induced neutropenia. The PDUFA target action date for the ROLONTIS BLA has been set for October 24, 2020. “If approved, ROLONTIS could be the first novel granulocyte colony-stimulating factor (G-CSF) available to healthcare providers in over 15 years,” said Joe Turgeon. “We have confidence in the future of ROLONTIS and are looking forward to potentially competing in this multibillion-dollar market.”

Niemand mehr hier?

Das bezieht sich auf dein EK!!

Und morgen ;). ?

Zur Info.: Gestern über 17 u.heute noch über 16....

Bin gestern tatsächlich noch bei 15,2 draufgesprungen

Is ja vielleicht noch nicht zuende.

Positive Phase 2 Krebs...

Krass...schade

Was geht denn hier heute ab?

Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) climbed 22% to close at $8.96 following the release of 2Q earnings where it recorded revenues of $34.3m. The company also confirmed that its Phase 3 trial of ROLONTIS for the management of chemotherapy-induced neutropenia is due to report top-line data in Q1 2018.